Istradefylline: all 25 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Enhancing Rehabilitation in Aging Study (ERAS)Not yet recruitingNCT07704385Phase 1/2
• Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord InjuryNot yet recruitingNCT05217498Phase 1/2
• Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedNCT02610231Phase 3Results posted
• A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseCompletedNCT01968031Phase 3Results posted
• An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001TerminatedNCT00199381Phase 3Results posted
• Istradefylline Effect Protocol on Parkinson's Disease TremorCompletedNCT05885360Phase 4
• Adenosine 2A Receptor Antagonism and AIH in ALSActive, not recruitingNCT05377424Phase 1/2
• A Study to Evaluate Abuse Potential of IstradefyllineCompletedNCT02609477Phase 1
• Effect of Mild Hepatic Impairment on the Pharmacokinetics of IstradefyllineCompletedNCT02256033Phase 1
• Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease PatientsCompletedNCT00957203Phase 3
• Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00955526Phase 3
• A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa TherapyCompletedNCT00955045Phase 2/3
• 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaCompletedNCT00456794Phase 2
• 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaCompletedNCT00456586Phase 2
• A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00455507Phase 2
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseCompletedNCT00250393Phase 2
• Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on LevodopaCompletedNCT00203957Phase 3
• Study of Istradefylline (KW-6002) for the Treatment of Restless Legs SyndromeCompletedNCT00199446Phase 2
• A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) PatientsCompletedNCT00199433Phase 2
• A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaCompletedNCT00199420Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00199407Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseaseCompletedNCT00199394Phase 3
• An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018CompletedNCT00199368Phase 3
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00199355Phase 2
• KW-6002 to Treat Parkinson's DiseaseCompletedNCT00006337Phase 2

← Istradefylline overview